Jeet Mukherjee
Stock Analyst at BTIG
(4.53)
# 245
Out of 5,090 analysts
13
Total ratings
69.23%
Success rate
21.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Initiates: Buy | $26 | $12.40 | +109.76% | 1 | Nov 7, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $27 | $18.00 | +50.00% | 3 | Nov 4, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $12.62 | +10.98% | 2 | Oct 30, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $59 → $75 | $66.56 | +12.68% | 2 | Oct 22, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $2.39 | +485.77% | 2 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $87 → $104 | $79.63 | +30.60% | 3 | Sep 25, 2025 |
Aardvark Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $26
Current: $12.40
Upside: +109.76%
Nurix Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $27
Current: $18.00
Upside: +50.00%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $12.62
Upside: +10.98%
Kymera Therapeutics
Oct 22, 2025
Maintains: Buy
Price Target: $59 → $75
Current: $66.56
Upside: +12.68%
Perspective Therapeutics
Oct 13, 2025
Reiterates: Buy
Price Target: $14
Current: $2.39
Upside: +485.77%
Monopar Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $87 → $104
Current: $79.63
Upside: +30.60%